Accidentes laborales, medicamentos y hábitos de salud

Individual Evaluation of the Pharmacological Risk of Patients of a home care service in the city of Cartagena

“…Currently, there are scales or strategies that evaluate some risks in specific population groups, related to increased mortality, greater functional and cognitive deterioration, greater hospital admissions, greater use of medical consultation and emergency services (40)(41)(42)(43)(44)(45), but they do not consider some important variables that are found during pharmaceutical care; The IPRES of the DETI method integrates relevant variables, such as: Sociodemographic, Clinical and Use of Health Services Variables and related to medication, allowing an Individual and comprehensive evaluation of the pharmacological risk to which a patient is exposed in an efficient manner, providing In addition, criteria that during Pharmaceutical care allow for the identification of variables that are susceptible to modification in order to minimize or eliminate risks and in turn would lead to monitoring of signs and symptoms suggestive of events associated with pharmacotherapy, guiding the definition of actions. Specific Pharmaceutical Care on patients and define the need for Pharmaceutical Care and the frequency of pharmaceutical follow-up required, something that is not evident in the reviewed literature.…”

“…Currently, there are scales or strategies that evaluate some risks in specific population groups, related to increased mortality, greater functional and cognitive deterioration, greater hospital admissions, greater use of medical consultation and emergency services such as, Vulnerable Population Group (5 -8), Pluripathological Patients (9)(10)(11)(12), Barthel Scale (13), Physiological Conditions that affect the pharmacokinetics of the medications received (14)(15)(16)(17)(18)(19), hyperfrequent users or Polyconsultants (20,21), Polypharmacy (22,23), Narrow-range Drugs (24), Lists of High-Risk Drugs (25-27), Haynes-Sackett Test, Morisky-Green Test, Anticholinergic Risk Scale (28)(29)(30)(31)(32), Drug Interactions of Clinical Relevance (33), the STOPP START criteria (34)(35)(36)(37)(38)(39), Beers Criteria (40,41), DRUID Criteria (42)(43)(44), The Medication Regimen Complexity Index (45), among others; but they do not consider some important variables that are found during pharmaceutical care, which is why the Individual Pharmacological Risk Evaluation Scale (IPRES) of the DETI Method of Pharmaceutical Care and Pharmacotherapeutic Follow-up, by integrating the Sociodemographic, Clinical and Utilization Variables of Health Services and related to medication, allows an individual and comprehensive evaluation of the pharmacological risk to which a patient is exposed.…”